文献速递心脑血管急症

CYP2C19 功能缺失代谢型与中国患者替格瑞洛-阿司匹林对比氯吡格雷-阿司匹林卒中风险的关联:随机临床试验的预设二次分析

Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2023-06-01
一句话结论在 CYP2C19 功能缺失的 TIA 或轻型缺血性卒中患者中,替格瑞洛-阿司匹林较氯吡格雷-阿司匹林降低卒中风险,且中间代谢型与慢代谢型间无差异,但任何出血风险均升高。

该研究为 CHANCE-2 随机临床试验的预设二次分析,纳入中国 202 个中心、6412 例 CYP2C19 功能缺失的 TIA 或轻型缺血性卒中患者,按代谢型分为中间代谢型(5001 例,78.0%)和慢代谢型(1411 例,22.0%)。患者 1:1 随机接受替格瑞洛-阿司匹林或氯吡格雷-阿司匹林治疗,主要疗效终点为新发缺血或出血性卒中。结果替格瑞洛-阿司匹林组主要终点发生率在中间代谢型为 6.0% vs 7.6%(HR 0.78,95%CI 0.63-0.97),慢代谢型为 5.7% vs 7.5%(HR 0.77,95%CI 0.50-1.18),交互作用 P=0.88;任何出血风险在中间代谢型 HR 2.14(95%CI 1.59-2.89),慢代谢型 HR 2.99(95%CI 1.51-5.93),交互作用 P=0.66。结论认为替格瑞洛-阿司匹林相对氯吡格雷-阿司匹林的疗效与安全性在不同 CYP2C19 基因型间一致。

要点

  • 在 CYP2C19 功能缺失的 TIA 或轻型缺血性卒中患者中,替格瑞洛-阿司匹林较氯吡格雷-阿司匹林降低主要卒中终点:中间代谢型 6.0% vs 7.6%(HR 0.78,95%CI 0.63-0.97),慢代谢型 5.7% vs 7.5%(HR 0.77,95%CI 0.50-1.18)。
  • 替格瑞洛-阿司匹林较氯吡格雷-阿司匹林增加任何出血风险:中间代谢型 5.4% vs 2.6%(HR 2.14,95%CI 1.59-2.89),慢代谢型 5.0% vs 2.0%(HR 2.99,95%CI 1.51-5.93)。
  • 代谢型与治疗分配间无交互作用:主要疗效终点交互作用 P=0.88,任何出血交互作用 P=0.66。
  • 慢代谢型患者中替格瑞洛-阿司匹林的主要卒中终点 HR 0.77(95%CI 0.50-1.18),置信区间跨 1,未达统计学显著。
  • 该分析为 CHANCE-2 试验的预设二次分析,结论支持替格瑞洛-阿司匹林相对氯吡格雷-阿司匹林的疗效与安全性在不同 CYP2C19 基因型间一致。

适用人群与场景

  • 中国 202 个中心纳入的 TIA 或轻型缺血性卒中患者,且根据即时基因分型携带至少一个 *2 或 *3 等位基因(*1/*2、*1/*3、*2/*2、*2/*3 或 *3/*3)。
  • 按等位基因分为中间代谢型(一个 *2 或 *3 等位基因,*1/*2 或 *1/*3)和慢代谢型(至少两个 *2 或 *3 等位基因,*2/*2、*2/*3 或 *3/*3)。

处置流程与药物剂量

  • 替格瑞洛组:第 1 天负荷剂量 180 mg,第 2-90 天 90 mg 每日两次。
  • 氯吡格雷组:第 1 天负荷剂量 300 mg,第 2-90 天 75 mg 每日一次。
  • 所有患者均接受阿司匹林:负荷剂量 75-300 mg,随后 75 mg 每日一次,共 21 天。

研究设计与关键结果

  • 研究类型:CHANCE-2 随机临床试验的预设二次分析;多中心、双盲、双模拟、安慰剂对照;中国 202 个中心;2019 年 9 月 23 日至 2021 年 3 月 22 日纳入;共 6412 例患者,中位年龄 64.8 岁(IQR 57.0-71.4 岁),男性 4242 例(66.2%)。
  • 代谢型分布:中间代谢型 5001 例(78.0%),慢代谢型 1411 例(22.0%)。
  • 主要疗效终点(新发缺血或出血性卒中):中间代谢型替格瑞洛-阿司匹林组 6.0%(150/2486) vs 氯吡格雷-阿司匹林组 7.6%(191/2515),HR 0.78(95%CI 0.63-0.97);慢代谢型 5.7%(41/719) vs 7.5%(52/692),HR 0.77(95%CI 0.50-1.18);交互作用 P=0.88。
  • 任何出血事件:中间代谢型替格瑞洛-阿司匹林组 5.4%(134/2486) vs 氯吡格雷-阿司匹林组 2.6%(66/2512),HR 2.14(95%CI 1.59-2.89);慢代谢型 5.0%(36/719) vs 2.0%(14/692),HR 2.99(95%CI 1.51-5.93);交互作用 P=0.66。
  • 分析按意向治疗原则进行。

证据类型、等级与局限

  • 证据类型:随机临床试验的预设二次分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于 CYP2C19 功能缺失的 TIA 或轻型缺血性卒中患者,替格瑞洛-阿司匹林较氯吡格雷-阿司匹林降低新发卒中风险,但增加任何出血风险,且疗效与安全性在不同代谢型间一致。

指南或共识出处

  • CHANCE-2 试验(Clopidogrel With Aspirin in High-Risk Patients With Acute Nondisabling Cerebrovascular Events II),ClinicalTrials.gov 注册号 NCT04078737。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The Clopidogrel With Aspirin in High-Risk Patients With Acute Nondisabling Cerebrovascular Events II (CHANCE-2) trial showed that ticagrelor-aspirin combination therapy reduced the risk of stroke compared with a clopidogrel-aspirin combination among carriers of CYP2C19 loss-of-function (LOF) alleles after a transient ischemic attack (TIA) or minor ischemic stroke. However, the association between the degree of CYP2C19 LOF and ideal treatment allocation remains unknown.

OBJECTIVE: To investigate whether the efficacy and safety of ticagrelor-aspirin vs clopidogrel-aspirin are consistent with the expected degree of CYP2C19 LOF after TIA or minor stroke.

DESIGN, SETTING, AND PARTICIPANTS: CHANCE-2 was a multicenter, double-blind, double-dummy, placebo-controlled randomized clinical trial. Patients were enrolled at 202 centers in China from September 23, 2019, through March 22, 2021. Patients with at least two *2 or *3 alleles (*2/*2, *2/*3, or *3/*3) according to point-of-care genotyping were classified as "poor metabolizers," and those with one *2 or *3 allele (*1/*2 or *1/*3) were classified as "intermediate metabolizers."

INTERVENTIONS: Patients were randomly assigned in a 1:1 ratio to receive ticagrelor (180-mg loading dose on day 1 followed by 90 mg twice daily for days 2-90) or clopidogrel (300-mg loading dose on day 1 followed by 75 mg/d for days 2-90). All patients received aspirin (75- to 300-mg loading dose followed by 75 mg/d for 21 days).

MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was a new ischemic or hemorrhagic stroke. The secondary efficacy outcome was a composite of new clinical vascular events and individual ischemic stroke events within 3 months. The primary safety outcome was severe or moderate bleeding. Analyses were performed according to the intention-to-treat principle.

RESULTS: Of the 6412 patients enrolled, the median age was 64.8 years (IQR, 57.0-71.4 years), and 4242 patients (66.2%) were men. Of the 6412 patients, 5001 (78.0%) were intermediate metabolizers, and 1411 (22.0%) were poor metabolizers. The primary outcome occurred less often with ticagrelor-aspirin vs clopidogrel-aspirin, irrespective of metabolizer status (6.0% [150 of 2486] vs 7.6% [191 of 2515]; hazard ratio [HR], 0.78 [95% CI, 0.63-0.97] among intermediate metabolizers and 5.7% [41 of 719] vs 7.5% [52 of 692]; HR, 0.77 [95% CI, 0.50-1.18] among poor metabolizers; P = .88 for interaction). Patients taking ticagrelor-aspirin had a higher risk of any bleeding event compared with those taking clopidogrel-aspirin, irrespective of metabolizer status: 5.4% (134 of 2486) vs 2.6% (66 of 2512) (HR, 2.14 [95% CI, 1.59-2.89]) among intermediate metabolizers and 5.0% (36 of 719) vs 2.0% (14 of 692) (HR, 2.99 [95% CI, 1.51-5.93]) among poor metabolizers (P = .66 for interaction).

CONCLUSIONS AND RELEVANCE: This prespecified analysis of a randomized clinical trial found no difference in treatment effect between poor and intermediate CYP2C19 metabolizers. The relative clinical efficacy and safety of ticagrelor-aspirin vs clopidogrel-aspirin were consistent across CYP2C19 genotypes.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04078737.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Xie X, Johnston SC, Wang A, et al. Association of CYP2C19 Loss-of-Function Metabolizer Status With Stroke Risk Among Chinese Patients Treated With Ticagrelor-Aspirin vs Clopidogrel-Aspirin: A Prespecified Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2023. PMID: 37279000. doi:10.1001/jamanetworkopen.2023.17037

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。